Increased circulating resistin levels in early-onset breast cancer patients of normal body mass index correlate with lymph node negative involvement and longer disease free survival: a multi-center POSH cohort serum proteomics study

Table 2 Clinical characteristics of the validation cohort

Clinical characteristics	Good outcome group	Poor outcome group	p value
n	90	91
Age (years)
Median	37	35	0.35
Range	26–40	18–40	0.35
Relapse (years)
Median	9.2	1.0	< 0.0001
Range	5.0–11.2	0.3–2.0	< 0.0001
BMI (kg/m²)*
Mean	23.3	23.2	0.84
SD	2.1	2.3	0.84
Histology
Invasive ductal carcinoma	83	83
Invasive lobular carcinoma	6	7
Unknown	1	1
Grade 1	2	1
Grade 2	30	16
Grade 3	57	73
Unknown	1	1
Lymph node status
Negative	45	26	0.001
Positive	45	65
Undetermined	0	0
ER status
Positive	59	41	0.003
Negative	31	50
Unknown	0	0
PR status
Positive	42	24	0.001
Negative	32	52
Unknown	16	15
HER2 receptor status
Positive	24	35	0.47
Negative	49	49
Unknown	17	7
Triple-negative tumours	17	22
Resection margin
R0 resection	67	67
R1 resection	7	12
Unknown	16	12
Chemotherapy
FEC	27	28
ECMF	22	18
FEC + docetaxel	5	14
AC	5	5
EC + paclitaxel	5	4
EC + paclitaxel + gemcitabine	2	4
EC	5	1
Null	10	2
Other	9	15

A adriamycin, BI body mass index, C cyclophosphamide, E epirubicin, ER oestrogen receptor, F 5-fluorouracil, HER2 human epidermal growth factor receptor 2, M methotrexate, PR progesterone receptor, SD standard deviation
*p = 0.13 between groups (unpaired t test)

ISSN: 1465-542X